Home Medizin LTBR wurde als potenzielles Ziel für die Krebsimmuntherapie und Marker für eine schlechte Prognose identifiziert

LTBR wurde als potenzielles Ziel für die Krebsimmuntherapie und Marker für eine schlechte Prognose identifiziert

von NFI Redaktion


A new research paper has been published in the journal Altern (listed on MEDLINE/PubMed as „Aging (Albany NY)“ and „Aging-US“ by Web of Science) Volume 16, Issue 1, titled „Systematic analysis of the prognostic value and immunological function of LTBR in human cancer.“

The Lymphotoxin-Beta-Receptor (LTBR) is a positive T-cell proliferation regulator gene closely associated with the tumor immune microenvironment. However, its role in cancer and immunotherapy is unclear.

In this new study, researchers Yinteng Wu, Shijian Zhao, Wenliang Guo, Ying Liu, Marìa Del Mar Requena Mullor, Raquel Alarcòn Rodrìguez, and Ruqiong Wei from the First Affiliated Hospital of Guangxi Medical University, the Eighth Affiliated Hospital of Guangxi Medical University, and the University of Almería, analyzed the expression level and prognostic value of LTBR in clinical stages, immune subtypes, and molecular subtypes. They also analyzed the correlation between LTBR and immunoregulatory genes, immune checkpoint genes, and RNA modification genes. Correlations between LTBR and immune cells, scores, cancer-related functional status, tumor stemness index, mismatch repair (MMR) genes, and DNA methyltransferase were also analyzed.

Furthermore, the team scrutinized the role of LTBR in DNA methylation, mutation status, tumor mutation burden (TMB), and microsatellite instability (MSI). Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), and Gene Set Enrichment Analysis (GSEA) were used to investigate the role of LTBR in pan-cancer. Finally, drugs associated with LTBR were also analyzed.

„In this work, we have examined the expression of LTBR at multiple levels.“

The expression of LTBR was confirmed by quantitative real-time PCR and Western Blot. LTBR is significantly overexpressed in most cancers and associated with a low patient survival rate. Additionally, LTBR expression strongly correlated with immune cells, score, cancer-related functional status, tumor stemness index, MMR genes, DNA methyltransferase, DNA methylation, mutation status, TMB, and MSI. Enrichment analysis revealed that LTBR was linked to apoptosis, necroptosis, and immune-related signaling pathways. Finally, several drugs targeting LTBR were identified. LTBR is overexpressed in multiple tumors and is associated with a poor prognosis. It is linked to immune-related genes and immune cell infiltration.

„In particular, we have identified LTBR as a potential target for cancer immunotherapy and as a marker for immune infiltration and poor prognosis. This study offers new opportunities for the diagnosis and treatment of cancer patients and raises hopes for improved outcomes.“

Source:

Journal reference:

Wu, Y., et al. (2024). Systematic analysis of the prognostic value and immunological function of LTBR in human cancer. Altern. doi.org/10.18632/aging.205356.

Related Posts

Adblock Detected

Please support us by disabling your AdBlocker extension from your browsers for our website.